The Global Hypothyroidism Market is expected to grow at a CAGR of 4.6% during the forecast period. Increasing prevalence of hypothyroidism, advancements in healthcare facilities, and favorable reimbursement and funding policies are expected to drive the market growth over the forecast period. According to information suggested by the 2022 guideline of the American Thyroid Association (ATA), 20 million Americans had some form of hypothyroidism disorder. However, side-effects related to available therapeutics can restrain the market growth over the assessment period.